The company’s top-line performance saw significant momentum, with revenue reaching ¥7.31 billion, up from ¥5.81 billion a year earlier. This growth filtered down to the bottom line, allowing Wakamoto to post an operating profit of ¥187 million, successfully reversing a ¥341 million operating loss recorded in the previous cycle.

Pretax figures also reflected the recovery, coming in at ¥222 million against a prior loss of ¥297 million. Consequently, earnings per share jumped to ¥6.19, a substantial increase from the ¥0.55 reported last year, according to the company's financial statement prepared under Japanese accounting standards.

Dividend Outlook and Shareholder Returns

Despite the improved profitability, the firm has maintained a conservative stance on its payout strategy. Wakamoto confirmed its year-end dividend forecast at ¥3.00 per share, bringing the total annual dividend to ¥3.00, unchanged from the previous fiscal year.

The results suggest a period of operational stabilization for the Tokyo-listed company (4512.TO) as it navigates a competitive domestic pharmaceutical landscape. All forward-looking dividend figures remain subject to final board approval at the close of the fiscal year.